WOS was first described in 2008 as a deposit within neoplastic gastric epithelium that obscures visualization of the microvasculature.[@bib1] It has since been described in esophageal adenocarcinoma, colonic neoplasms, and gastric intestinal metaplasia.[@bib2], [@bib3], [@bib4] The phenomenon of WOS has been shown to be due to intraepithelial lipid deposition, for which its exact clinical significance has yet to be identified.[@bib5]

The pathologic description of GI xanthelasmas, which are the subepithelial accumulation of lipid-laden histiocytes, dates back to 1887.[@bib6] The term "gastric xanthelasmas" was introduced decades later, in 1969, by Kimura et al.[@bib7] Since then, gastric xanthelasmas have been widely reported, with a prevalence of up to 7%.[@bib8] Esophageal xanthelasmas were first described in 1984, and since then 22 cases have been reported in the literature.[@bib9], [@bib10] Esophageal xanthomas are rarely larger than 5 mm, and the largest reported was 20 mm.[@bib9]

Here we present a unique esophageal lesion in which both WOS (intraepithelial lipid) and xanthelasmas (subepithelial lipid-laden histiocytes) were present within a 3.5-cm area of low-grade dysplasia in a C5M6 Barrett's lesion in a 70-year-old man who underwent upper endoscopy for chronic reflux symptoms ([Video 1](#appsec1){ref-type="sec"}, available online at [www.VideoGIE.org](http://www.videogie.org){#intref0015}). Endoscopy demonstrated a yellow nodular Paris IIa lesion on the posterolateral wall that was 3.5 cm long. With magnification, areas with WOS and irregular microsurface ([Figs. 1](#fig1){ref-type="fig"}A-C) were visualized. In regions where the WOS was not heavily deposited, an irregular microvasculature was visible ([Figs. 1](#fig1){ref-type="fig"}D and E) on a yellowish background of the xanthelasma. This lesion was removed en bloc by endoscopic submucosal dissection ([Fig. 1](#fig1){ref-type="fig"}F). Pathologic examination demonstrated Barrett's esophagus with low-grade dysplasia and the presence of heavy intraepithelial lipid deposits and subepithelial lipid-laden histiocytes ([Fig. 2](#fig2){ref-type="fig"}).Figure 1**A-C,** Dysplastic Barrett's lesion with white opaque substance (WOS) (*red arrows*) on the posterolateral wall. **D-E,** Areas with irregular, dilated tortuous microvasculature visible. **F,** Gross resected specimen.Figure 2**A, B,** Dysplastic Barrett's epithelium with subepithelial lamina propria xanthomas causing a polypoid configuration (**A,** hematoxylin phloxine saffron, orig. mag. ×40; **B,** orig. mag. ×200). **C,** Diastase-pretreated periodic acid-Schiff stain of dysplastic epithelium demonstrating nonstaining focal basal subnuclear vacuoles of lipid (hematoxylin phloxine saffron, orig. mag. ×400).
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